Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Pfizer has agreed to pay up to $250mn to settle more than 10,000 US lawsuits over cancer risks associated ...
Pfizer (NYSE:PFE) will pay up to $250M to settle more than 10,000 U.S. lawsuits alleging that the company concealed cancer risks associated with its now-discontinued heartburn drug Zantac.
GSK (NYSE:GSK) said it has started to appeal a recent court ruling in Delaware that allowed tens of thousands of lawsuits to ...
GSK and other drugmakers have kickstarted the process to appeal a US court's decision to allow more than 70,000 ...
The decision of a Delaware judge on Friday to allow more than 75,000 Zantac lawsuits to go forward to jury trials has left ...
GSK Plc, Pfizer Inc. and other drugmakers must face trials in state court in Delaware after a judge found the evidence ...
A look at similar cases might suggest this latest ruling could cost GSK tens of billions of dollars in potential liabilities.
A woman who claimed in a lawsuit that GSK's discontinued heartburn drug Zantac caused her breast cancer dropped her case ...
A woman who claimed in a lawsuit that GSK’s discontinued heartburn drug Zantac caused her breast cancer dropped her case ...
GSK’s shares fell sharply following a judge's decision to allow more than 70,000 lawsuits to proceed, alleging it’s Zantac ...
Along with GSK and Pfizer, Sanofi and Boehringer Ingelheim GmbH have been sued by consumers. After the federal cases were ...
A woman who claimed in a lawsuit that GSK's discontinued heartburn drug Zantac caused her breast cancer dropped her case ...